Novonesis Beheer
Beheer criteriumcontroles 3/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
Ester Baiget
Algemeen directeur
€3.9m
Totale compensatie
Percentage CEO-salaris | 33.3% |
Dienstverband CEO | 4.8yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 3.6yrs |
Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued
Sep 05Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
May 02Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Apr 07Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?
Mar 12Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues
Feb 04Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jan 29Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture
Dec 05A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Oct 14These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence
Aug 29Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jul 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
May 29Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Apr 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | €283m |
Mar 31 2024 | n/a | n/a | €332m |
Dec 31 2023 | €4m | €1m | €406m |
Sep 30 2023 | n/a | n/a | €430m |
Jun 30 2023 | n/a | n/a | €460m |
Mar 31 2023 | n/a | n/a | €487m |
Dec 31 2022 | €3m | €1m | €494m |
Sep 30 2022 | n/a | n/a | €460m |
Jun 30 2022 | n/a | n/a | €418m |
Mar 31 2022 | n/a | n/a | €416m |
Dec 31 2021 | €3m | €1m | €423m |
Sep 30 2021 | n/a | n/a | €427m |
Jun 30 2021 | n/a | n/a | €409m |
Mar 31 2021 | n/a | n/a | €389m |
Dec 31 2020 | €3m | €927k | €380m |
Compensatie versus markt: Ester's total compensation ($USD4.23M) is about average for companies of similar size in the Danish market ($USD3.61M).
Compensatie versus inkomsten: Ester's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Ester Baiget (53 yo)
4.8yrs
Tenure
€3,903,958
Compensatie
Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President & CEO | 4.8yrs | €3.90m | geen gegevens | |
Executive VP & CFO | less than a year | €858.60k | geen gegevens | |
Chief Operating Officer | less than a year | €1.03m | geen gegevens | |
Chief Scientific Officer | 4.2yrs | geen gegevens | geen gegevens | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Vice President of Global Sales & Marketing | no data | geen gegevens | geen gegevens | |
Executive Vice President of People & Stakeholder Relations | 3.6yrs | geen gegevens | geen gegevens | |
Executive Vice President of Planetary Health Biosolutions | 8.8yrs | €1.02m | geen gegevens | |
Executive Vice President of Human Health Biosolutions | 3.6yrs | geen gegevens | geen gegevens | |
Executive Vice President of Strategy & Integration | less than a year | geen gegevens | geen gegevens | |
Executive Vice President of Food & Beverage Biosolutions | less than a year | geen gegevens | geen gegevens | |
Chief Executive Officer of Albumedix | 8.8yrs | geen gegevens | geen gegevens |
3.6yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren management: NSIS B's management team is considered experienced (3.6 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Vice Chair of the Board | less than a year | geen gegevens | geen gegevens | |
Independent Chairman | 4.8yrs | €239.07k | 0.0011% DKK 2.2m | |
Independent Director | 7.8yrs | €173.33k | geen gegevens | |
Director | 7.8yrs | €107.73k | 0.00023% DKK 461.7k | |
Director | 4.8yrs | €143.55k | 0.00065% DKK 1.3m | |
Director | less than a year | geen gegevens | geen gegevens | |
Employee Representative Director | 11.8yrs | €66.91k | geen gegevens | |
Employee Representative Director | 11.8yrs | €71.77k | geen gegevens | |
Independent Director | 4.8yrs | €143.55k | geen gegevens | |
Employee Representative Director | 3.7yrs | €107.73k | 0.000090% DKK 180.7k | |
Employee Representative Director | 3.7yrs | €71.77k | 0.00012% DKK 240.9k | |
Independent Director | 2.7yrs | €137.51k | 0.00022% DKK 441.7k |
4.8yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: NSIS B's board of directors are considered experienced (4.8 years average tenure).